Adverse events2,365

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 2,365

Type	Event	Organ system	Group	Affected	At risk	Events
other	ANAEMIA	Blood and lymphatic system disorders	Safety Run-in: Increased TLS Risk at Baseline	4	15	20
other	ANAEMIA	Blood and lymphatic system disorders	Safety Run-in: Low TLS Risk at Baseline	2	6	2
other	ANAEMIA	Blood and lymphatic system disorders	Randomization Phase: Ibrutinb + Venetoclax	27	134	40
other	ANAEMIA	Blood and lymphatic system disorders	Randomization Phase: Ibrutinib + Placebo	17	132	32
other	ANAEMIA	Blood and lymphatic system disorders	Treatment-naive Open-label Arm	17	78	27
other	INCREASED TENDENCY TO BRUISE	Blood and lymphatic system disorders	Safety Run-in: Increased TLS Risk at Baseline	3	15	4
other	INCREASED TENDENCY TO BRUISE	Blood and lymphatic system disorders	Safety Run-in: Low TLS Risk at Baseline	3	6	4
other	INCREASED TENDENCY TO BRUISE	Blood and lymphatic system disorders	Randomization Phase: Ibrutinb + Venetoclax	12	134	17
other	INCREASED TENDENCY TO BRUISE	Blood and lymphatic system disorders	Randomization Phase: Ibrutinib + Placebo	10	132	12
other	INCREASED TENDENCY TO BRUISE	Blood and lymphatic system disorders	Treatment-naive Open-label Arm	17	78	25
other	LEUKOPENIA	Blood and lymphatic system disorders	Safety Run-in: Increased TLS Risk at Baseline	1	15	1
other	LEUKOPENIA	Blood and lymphatic system disorders	Safety Run-in: Low TLS Risk at Baseline	0	6	0
other	LEUKOPENIA	Blood and lymphatic system disorders	Randomization Phase: Ibrutinb + Venetoclax	12	134	53
other	LEUKOPENIA	Blood and lymphatic system disorders	Randomization Phase: Ibrutinib + Placebo	1	132	2
other	LEUKOPENIA	Blood and lymphatic system disorders	Treatment-naive Open-label Arm	2	78	2
other	LYMPHADENOPATHY	Blood and lymphatic system disorders	Safety Run-in: Increased TLS Risk at Baseline	0	15	0
other	LYMPHADENOPATHY	Blood and lymphatic system disorders	Safety Run-in: Low TLS Risk at Baseline	1	6	1
other	LYMPHADENOPATHY	Blood and lymphatic system disorders	Randomization Phase: Ibrutinb + Venetoclax	2	134	2
other	LYMPHADENOPATHY	Blood and lymphatic system disorders	Randomization Phase: Ibrutinib + Placebo	4	132	4
other	LYMPHADENOPATHY	Blood and lymphatic system disorders	Treatment-naive Open-label Arm	2	78	2

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03112174/events

API reference For AI assistants

Adverse events2,365

Sources 3

Read this list from software.